The Fort Worth Press - New to The Street and IGC Pharma (NYSE American:IGC) Launch Strategic 12-Part National Media Partnership to Accelerate Investor Awareness and Market Positioning

USD -
AED 3.672499
AFN 66.498782
ALL 80.629676
AMD 365.091035
AOA 917.000408
ARS 1492.336499
AUD 1.414877
AWG 1.80125
AZN 1.701052
BAM 1.691649
BBD 2.00813
BDT 123.418242
BHD 0.375989
BIF 2985.079791
BMD 1
BND 1.277602
BOB 11.849673
BRL 5.083698
BSD 0.997016
BTN 94.875232
BWP 13.457596
BYN 2.968819
BYR 19600
BZD 2.00519
CAD 1.39518
CDF 2262.499098
CHF 0.808199
CLF 0.023198
CLP 912.999827
CNY 6.747602
CNH 6.743155
COP 3157.68
CRC 453.228387
CUC 1
CUP 26.5
CVE 95.372573
CZK 20.984797
DJF 177.546166
DKK 6.46806
DOP 58.20179
DZD 132.308956
EGP 49.569799
ERN 15
ETB 160.923669
EUR 0.86521
FJD 2.20855
FKP 0.74148
GBP 0.741195
GEL 2.610161
GGP 0.74148
GHS 11.700039
GIP 0.74148
GMD 73.496802
GNF 8756.649224
GTQ 7.607144
GYD 208.588851
HKD 7.845875
HNL 26.723176
HRK 6.519601
HTG 130.363707
HUF 314.212956
IDR 17801
ILS 2.99985
IMP 0.74148
INR 95.21055
IQD 1306.058902
IRR 1375550.000465
ISK 123.37984
JEP 0.74148
JMD 158.335856
JOD 0.708953
JPY 157.888997
KES 128.789741
KGS 87.449779
KHR 4049.647537
KMF 425.999543
KRW 1411.360366
KWD 0.30866
KYD 0.830861
KZT 467.275008
LAK 22510.919863
LBP 89282.792025
LKR 334.420274
LRD 179.959348
LSL 16.197552
LTL 2.95274
LVL 0.60489
LYD 6.341738
MAD 9.29222
MDL 17.337716
MGA 4254.638239
MKD 53.219738
MMK 2099.549369
MNT 3595.852714
MOP 8.056654
MRU 40.080439
MUR 46.795264
MVR 15.450064
MWK 1728.841413
MXN 17.138497
MYR 4.085099
MZN 63.904996
NAD 16.197552
NGN 1361.789707
NIO 36.690741
NOK 9.50157
NPR 151.800372
NZD 1.69811
OMR 0.382693
PAB 0.997016
PEN 3.376465
PGK 4.406003
PHP 60.814978
PKR 276.796523
PLN 3.719555
PYG 5928.296501
QAR 3.644596
RON 4.541503
RSD 101.492021
RUB 81.61994
RWF 1466.072741
SAR 3.744756
SBD 8.065696
SCR 14.449077
SDG 600.504962
SEK 9.48365
SGD 1.278665
SLE 24.60377
SOS 569.822255
SRD 37.866499
STD 20697.981008
STN 21.191022
SVC 8.723782
SZL 16.194265
THB 32.970555
TJS 9.197509
TMT 3.51
TND 2.929032
TRY 47.714698
TTD 6.757774
TWD 32.250104
TZS 2643.563029
UAH 44.653894
UGX 3714.050945
UYU 40.133201
UZS 11924.058297
VES 755.762399
VND 26204.5
VUV 118.557141
WST 2.733716
XAF 567.363231
XAG 0.015658
XAU 0.00023
XCD 2.70255
XCG 1.796912
XDR 0.705618
XOF 567.363231
XPF 103.152705
YER 238.395817
ZAR 16.14803
ZMK 9001.197294
ZMW 18.818492
ZWL 321.999592
  • CMSC

    0.0240

    21.744

    +0.11%

  • BCC

    2.3400

    86.6

    +2.7%

  • BCE

    -0.0200

    22.75

    -0.09%

  • JRI

    0.1500

    12.81

    +1.17%

  • RIO

    1.4500

    101.1

    +1.43%

  • CMSD

    -0.1600

    21.82

    -0.73%

  • GSK

    0.7900

    52.96

    +1.49%

  • BTI

    0.6000

    59.33

    +1.01%

  • NGG

    0.4700

    80.88

    +0.58%

  • RBGPF

    0.7600

    70.5

    +1.08%

  • RELX

    0.0485

    35.52

    +0.14%

  • BP

    -0.6000

    41.63

    -1.44%

  • RYCEF

    0.2300

    20.85

    +1.1%

  • VOD

    0.1900

    16.19

    +1.17%

  • AZN

    1.4100

    161.42

    +0.87%

New to The Street and IGC Pharma (NYSE American:IGC) Launch Strategic 12-Part National Media Partnership to Accelerate Investor Awareness and Market Positioning
New to The Street and IGC Pharma (NYSE American:IGC) Launch Strategic 12-Part National Media Partnership to Accelerate Investor Awareness and Market Positioning

New to The Street and IGC Pharma (NYSE American:IGC) Launch Strategic 12-Part National Media Partnership to Accelerate Investor Awareness and Market Positioning

NEW YORK, NY / ACCESS Newswire / March 25, 2026 / New to The Street, a premier financial media platform known for its national television distribution and integrated investor engagement strategy, today announced a strategic 12-part media partnership with IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage biotechnology company leveraging artificial intelligence to develop treatments for Alzheimer's disease and metabolic disorders.

Text size:

The multi-faceted campaign is designed to elevate IGC Pharma's visibility across institutional and retail investor audiences through a coordinated media strategy that includes long-form television interviews, national TV commercial distribution, high-impact outdoor billboard placements, and curated accredited investor events in key financial markets.

Through this initiative, IGC Pharma will be featured across New to The Street's sponsored programming on Fox Business and Bloomberg Television, alongside amplification to a combined digital audience exceeding 4.45 million YouTube subscribers. The campaign will also include dominant outdoor placements in Times Square and the New York City Financial District, as well as earned media distribution across major U.S. broadcast affiliates.

"This partnership represents a strategic step forward in expanding our visibility within the global investment community," said Ram Mukunda, CEO of IGC Pharma. "New to The Street's unmatched ability to combine television, digital distribution, and outdoor media provides us with a powerful platform to communicate our clinical progress, including our Phase 2 CALMA trial, and to position IGC Pharma at the forefront of AI-driven biopharmaceutical innovation."

"We are proud to launch this 12-part series with IGC Pharma at a time when Alzheimer's continues to impact millions of families across the United States and around the world," said Vince Caruso, co-founder and CEO of New to The Street. "This is about more than visibility - it's about bringing forward companies that are working on real solutions. IGC Pharma is advancing meaningful progress in an area of critical need, and through our platform, we aim to elevate their story to the global investment community while offering a sense of hope and potential comfort to those affected by this devastating disease."

New to The Street's integrated platform is engineered to align media exposure with capital markets objectives - driving narrative control, investor engagement, and long-term brand equity for emerging and growth-stage public companies.

About New to The Street

New to The Street is one of the longest-running U.S. and international sponsored television brands, broadcasting weekly as sponsored programming on Fox Business and Bloomberg Television. The platform delivers long-form interviews with innovative public and private companies, combining national TV exposure with digital, social, and outdoor media amplification.

With over 4.45 million YouTube subscribers and one of the most comprehensive media distribution ecosystems in the financial space, New to The Street integrates television broadcasting, earned media placements across ABC, NBC, and CBS affiliates, and dominant billboard visibility throughout Times Square and the NYC Financial District. The platform also provides direct access to accredited investors through curated in-person and virtual events, creating a full-cycle investor awareness and engagement solution.

About IGC Pharma

IGC Pharma, Inc. (NYSE American:IGC) is a clinical-stage biotechnology company leveraging artificial intelligence to develop innovative treatments for Alzheimer's disease and metabolic disorders.

The Company's lead therapeutic candidate, IGC-AD1, is currently in a Phase 2 clinical trial (CALMA) targeting agitation in Alzheimer's dementia. Its pipeline also includes TGR-63, focused on amyloid plaque reduction, along with additional early-stage programs addressing neurodegeneration, tau pathology, and metabolic dysfunction.

By integrating AI into drug discovery, clinical trial design, and patient targeting, IGC Pharma is accelerating development timelines and advancing a portfolio of therapies aimed at addressing significant unmet medical needs. The Company maintains a robust patent portfolio supporting its innovation-driven approach.

Media Contact
Monica Brennan
New to The Street
[email protected]

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of applicable securities laws. These statements are based on current expectations and assumptions that are subject to risks and uncertainties, which could cause actual results to differ materially. Investors are encouraged to review IGC Pharma's filings with the U.S. Securities and Exchange Commission for additional information regarding these risks.

SOURCE: New to The Street



View the original press release on ACCESS Newswire

H.M.Hernandez--TFWP